Literature DB >> 28727142

Genomic and transcriptomic heterogeneity of colorectal tumours arising in Lynch syndrome.

Hans Binder1, Lydia Hopp1, Michal R Schweiger2,3,4, Steve Hoffmann1, Frank Jühling1,5,6, Martin Kerick2,3,4, Bernd Timmermann4, Susann Siebert2,3,4, Christina Grimm2,3,4, Lilit Nersisyan7, Arsen Arakelyan7, Maria Herberg1, Peter Buske1, Henry Loeffler-Wirth1, Maciej Rosolowski8, Christoph Engel8, Jens Przybilla1, Martin Peifer2, Nicolaus Friedrichs2, Gabriela Moeslein9, Margarete Odenthal2, Michelle Hussong2,3,4, Sophia Peters10, Stefanie Holzapfel10, Jacob Nattermann11, Robert Hueneburg11, Wolff Schmiegel12, Brigitte Royer-Pokora13, Stefan Aretz10, Michael Kloth2, Matthias Kloor14,15,16, Reinhard Buettner2, Jörg Galle1, Markus Loeffler8.   

Abstract

Colorectal cancer (CRC) arising in Lynch syndrome (LS) comprises tumours with constitutional mutations in DNA mismatch repair genes. There is still a lack of whole-genome and transcriptome studies of LS-CRC to address questions about similarities and differences in mutation and gene expression characteristics between LS-CRC and sporadic CRC, about the molecular heterogeneity of LS-CRC, and about specific mechanisms of LS-CRC genesis linked to dysfunctional mismatch repair in LS colonic mucosa and the possible role of immune editing. Here, we provide a first molecular characterization of LS tumours and of matched tumour-distant reference colonic mucosa based on whole-genome DNA-sequencing and RNA-sequencing analyses. Our data support two subgroups of LS-CRCs, G1 and G2, whereby G1 tumours show a higher number of somatic mutations, a higher amount of microsatellite slippage, and a different mutation spectrum. The gene expression phenotypes support this difference. Reference mucosa of G1 shows a strong immune response associated with the expression of HLA and immune checkpoint genes and the invasion of CD4+ T cells. Such an immune response is not observed in LS tumours, G2 reference and normal (non-Lynch) mucosa, and sporadic CRC. We hypothesize that G1 tumours are edited for escape from a highly immunogenic microenvironment via loss of HLA presentation and T-cell exhaustion. In contrast, G2 tumours seem to develop in a less immunogenic microenvironment where tumour-promoting inflammation parallels tumourigenesis. Larger studies on non-neoplastic mucosa tissue of mutation carriers are required to better understand the early phases of emerging tumours.
Copyright © 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. Copyright © 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Keywords:  hereditary cancer; immune editing; mismatch repair; tumour heterogeneity

Mesh:

Substances:

Year:  2017        PMID: 28727142     DOI: 10.1002/path.4948

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  24 in total

Review 1.  Colorectal cancer: genetic abnormalities, tumor progression, tumor heterogeneity, clonal evolution and tumor-initiating cells.

Authors:  Ugo Testa; Elvira Pelosi; Germana Castelli
Journal:  Med Sci (Basel)       Date:  2018-04-13

2.  Immune Profiling of Premalignant Lesions in Patients With Lynch Syndrome.

Authors:  Kyle Chang; Melissa W Taggart; Laura Reyes-Uribe; Ester Borras; Erick Riquelme; Reagan M Barnett; Guido Leoni; F Anthony San Lucas; Maria T Catanese; Federica Mori; Maria G Diodoro; Y Nancy You; Ernest T Hawk; Jason Roszik; Paul Scheet; Scott Kopetz; Alfredo Nicosia; Elisa Scarselli; Patrick M Lynch; Florencia McAllister; Eduardo Vilar
Journal:  JAMA Oncol       Date:  2018-08-01       Impact factor: 31.777

Review 3.  Back to the Colorectal Cancer Consensus Molecular Subtype Future.

Authors:  David G Menter; Jennifer S Davis; Bradley M Broom; Michael J Overman; Jeffrey Morris; Scott Kopetz
Journal:  Curr Gastroenterol Rep       Date:  2019-01-30

Review 4.  Discovering the Mutational Profile of Early Colorectal Lesions: A Translational Impact.

Authors:  Chiara Alquati; Anna Prossomariti; Giulia Piazzi; Francesco Buttitta; Franco Bazzoli; Luigi Laghi; Luigi Ricciardiello
Journal:  Cancers (Basel)       Date:  2021-04-25       Impact factor: 6.639

5.  Familial Burden and Other Clinical Factors Associated With Various Types of Cancer in Individuals With Lynch Syndrome.

Authors:  Leah H Biller; Miki Horiguchi; Hajime Uno; Chinedu Ukaegbu; Sapna Syngal; Matthew B Yurgelun
Journal:  Gastroenterology       Date:  2021-03-29       Impact factor: 33.883

Review 6.  Hereditary Nonpolyposis Colorectal Cancer and Cancer Syndromes: Recent Basic and Clinical Discoveries.

Authors:  Erbao Chen; Xiaojing Xu; Tianshu Liu
Journal:  J Oncol       Date:  2018-04-23       Impact factor: 4.375

7.  Footprints of Sepsis Framed Within Community Acquired Pneumonia in the Blood Transcriptome.

Authors:  Lydia Hopp; Henry Loeffler-Wirth; Lilit Nersisyan; Arsen Arakelyan; Hans Binder
Journal:  Front Immunol       Date:  2018-07-17       Impact factor: 7.561

8.  Immunoprofiles of colorectal cancer from Lynch syndrome.

Authors:  Joanna Walkowska; Thomas Kallemose; Göran Jönsson; Mats Jönsson; Ove Andersen; Mads Hald Andersen; Inge Marie Svane; Anne Langkilde; Mef Nilbert; Christina Therkildsen
Journal:  Oncoimmunology       Date:  2018-09-26       Impact factor: 8.110

Review 9.  Advances in Identification of Susceptibility Gene Defects of Hereditary Colorectal Cancer.

Authors:  Qiang Liu; Yue-Qiu Tan
Journal:  J Cancer       Date:  2019-01-01       Impact factor: 4.207

10.  Combined Gemcitabine and Immune-Checkpoint Inhibition Conquers Anti-PD-L1 Resistance in Low-Immunogenic Mismatch Repair-Deficient Tumors.

Authors:  Inken Salewski; Julia Henne; Leonie Engster; Bjoern Schneider; Heiko Lemcke; Anna Skorska; Peggy Berlin; Larissa Henze; Christian Junghanss; Claudia Maletzki
Journal:  Int J Mol Sci       Date:  2021-06-01       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.